TECP
XENE icon

Trails Edge Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Trails Edge Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200,000
Closed -$11.6M – 40
2026
Q1 		$11.6M Buy
+200,000
New +$9.22M 2.66% 16

Other funds holding XENE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Trails Edge Capital Partners's XENE Position: Q2 2026 in Review

Trails Edge Capital Partners held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 440,000 shares worth $26.6M. The position accounts for 4.22% of the portfolio, ranked #8.

Trails Edge Capital Partners first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. The position peaked at $26.8M in Q4 2025. 286 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Trails Edge Capital Partners held 440,000 shares of Xenon Pharmaceuticals worth $26.6M as of Q2 2026.
  • Trails Edge Capital Partners left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up 4.22% of Trails Edge Capital Partners's portfolio in Q2 2026, its #8 holding.
  • Trails Edge Capital Partners first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Trails Edge Capital Partners's Xenon Pharmaceuticals position peaked at $26.8M in Q4 2025.
  • 286 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.